Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it ranked first in overall corporate reputation among U.S. patient groups who reported working with, or who were familiar with the company.
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the company has won an International Corporate Social Responsibility (CSR) Excellence Award for its partnership with Gift of Adoption to co-create
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the launch of the RAREis Global Advocate Grant, a new program designed to support the rare disease community by providing financial assistance
The new program and website are designed to create conversations that will lead to new resources to support diversity, equity, inclusion and allyship within the rare disease community . | February 28, 2022